Canakinumab

INN name:	Canakinumab
Lab codes:	ACZ-885
Trade name:	Ilaris
Chemical name:	Immunoglobulin G1, anti-(human interleukin-1beta (IL-12)) human monoclonal ACZ885; (1Glu>Glp)-gamma heavy chain (221-214')-disulfide with kappa light chain, dimer (227-227'':230-230'')-bisdisulfide
Molecular formula:	C6452 H9958 N1722 O2010 S42
Chemical Structure:	Heavy Chain QVQLVESGGGVVQPGRSLRLSCAASGFTFSVYGMNWVRQAPGKGLEWVAIIWYDGDNQYY ADSVKGRFTISRDNSKNTLYLQMNGLRAEDTAVYYCARDLRTGPFDYWGQGTLVTVSSAS TKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGL YSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPS VFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNST YRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMT KNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQ GNVFSCSVMHEALHNHYTQKSLSLSPGK Light Chain EIVLTQSPDFQSVTPKEKVTITCRASQSIGSSLHWYQQKPDQSPKLLIKYASQSFSGVPS RFSGSGSGTDFTLTINSLEAEDAAAYYCHQSSSLPFTFGPGTKVDIKRTVAAPSVFIFPP SDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLT LSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
CAS Registry Number:	914613-48-2
Originator:	Novartis
Developer:	Novartis
Class:	Anti-inflammatories
Mechanism of Action:	Interleukin 1 beta inhibitors
WHO ATC code:	L04AC08
EPhMRA code:	L4C
FDA approval:	Yes
Clinical Trials: Indication Phase Status Cryopyrin Associated Periodic Syndrome Phase 3 Completed Cryopyrin-associated Periodic Syndromes:|Familial Cold Autoinflammatory Syndrome|Muckle Wells Syndrome|Neonatal Onset Multisystem Inflammatory Disease Phase 3 Completed Hereditary Periodic Fevers Phase 3 Recruiting Systemic Juvenile Idiopathic Arthritis Phase 3 Completed Systemic Juvenile Idiopathic Arthritis Phase 3 Not yet recruiting Systemic Juvenile Idiopathic Arthritis With Active Flare Phase 3 Completed Diabetes Mellitus, Type 2|Atherosclerosis|Prediabetic State Phase 2 Completed Gout Phase 2 Completed NALP3 Mutation Phase 2 Completed Rheumatoid Arthritis Phase 2 Completed TNF-receptor Associated Periodic Syndromes (TRAPS) Phase 2 Completed Type 2 Diabetes Mellitus|Impaired Glucose Tolerance Phase 2 Completed Urticaria|Vasculitis Phase 2 Completed Chronic Obstructive Pulmonary Disease Phase 1|Phase 2 Completed
Product Patent Expiry: USA Sep 2024 (Term may be extended) South Korea Aug 2021 Canada Aug 2021 China Aug 2021 Japan Mar 2024* *** Term of the patents in the above countries may get extended, please contact us for update * Patent expiry including patent term extension It is possible to extend the term of a patent in USA, KR and JP. The extension granted at the time of writing this post has been included and marked with *. Please leave a comment below for any update.
Sales of the product (Source: From company report): Years Sales* 2009 3 2010 26 2011 48 2012 72 2013 119 2014 199 *USD millions